ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification of novel diclofenac acid and naproxen bearing hydrazones as 15-LOX inhibitors: Design, synthesis, in vitro evaluation, cytotoxicity, and in silico studies

Sardar, Asma; Abid, Obaid-ur-Rahman*; Daud, Saima; Shah, Basit Ali; Shahid, Wardah; Ashraf, Muhammad; Fatima, Mahvish; Ezzine, Safa; Wadood, Abdul; Shareef, Azam; Al-Ghulikah, Hanan A.; Alissa, Siham A.
Arabian Journal of Chemistry2022-12DOI: 10.1016/j.arabjc.2022.104300
3被引6阅读
引用收藏
分享

摘要

Inflammation is the immune system's adaptive response to tissue dysfunction or home-ostatic imbalance, inducing fever, pain, physiological and biochemical changes via the cyclooxyge-nase (COX) and lipoxygenase (LOX) pathways. NSAIDs (non-steroidal anti-inflammatory drugs), such as diclofenac acid and naproxen, are the most common inhibitors of the COX pathway. These drugs, however, are currently being studied as LOX inhibitors as well. Therefore, in the present study, a novel series of diclofenac acid and naproxen-bearing hydrazones 7(a-r) were designed, syn-thesized, and characterized by different spectroscopic methods like 1H NMR, 13C NMR, IR and HRMS (EI) analysis. All these synthesized compounds were evaluated for their in vitro inhibitory potential against the Soybean 15-lipoxygenase (15-LOX) enzyme. These compounds exhibited vary-ing degrees of inhibitory potential ranging from IC50 4.61 +/- 3.21 mu M to 193.62 +/- 4.68 mu M in com-parison to standard inhibitors quercetin (IC50 4.84 +/- 6.43 mu M) and baicalein (IC50 22.46 +/- 1. 32 mu M). The most potent compounds in the series were compounds 7c (IC50 4.61 +/- 3.21 mu M), and 7f (IC50 6.64 +/- 4.31 mu M). These compounds were found least cytotoxic and showed 96.42 +/- 1.3 % and 94.87 +/- 1.6 % viability to cells at 0.25 mM concentration respectively. ADME and in silico studies supported the drug-likeness and binding studies of the molecules with the target enzyme.

学科与关键词

关键词
Diclofenac acidNaproxenHydrazonesLOX inhibitorsMolecular docking studies
相关
加载中…
  • Exploring ibuprofen derivatives as α-glucosidase and lipoxygenase inhibitors: Cytotoxicity and in silico studies
    Daud, Saima; Abid, Obaid-ur-Rahman*; Sardar, Asma; Abdullah, Shawana; Shahid, Wardah; Ashraf, Muhammad*; Ejaz, Syeda Abida; Saeed, Amna; Shah, Basit Ali; Niaz, Basit*Archiv der Pharmazie, 2022, 355(8): e2200013.被引 4
  • Synthesis, anti-inflammatory screening, molecular docking, and COX-1,2/-5-LOX inhibition profile of some novel quinoline derivatives
    Chaaban, Ibrahim; Rizk, Ola H.*; Ibrahim, Tamer M.; Henen, Shery S.; El-Khawass, Sayeda M.; Bayad, Aida E.; El-Ashmawy, Ibrahim M.; Nematalla, Hisham A.Bioorganic Chemistry, 2018, 78: 220-235.被引 33
  • In vitro and In Silico Studies on Curcumin and Its Analogues as Dual Inhibitors for cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)
    Nunung Yuniarti; Perdana Adhi Nugroho; Aditya Asyhar; Sardjiman Sardjiman; Zullies Ikawati; Enade Perdana IstyastonoITB Journal of Sciences, 2012, 44(1): 51-66.
查看全部 →

发表信息

论文状态
公开发表
期刊
Arabian Journal of Chemistry
发表日期
2022-12
卷期
第 15 卷, 第 12 期
页码
104300
DOI
10.1016/j.arabjc.2022.104300
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Higher Education Commission Pakistan [4950, 5720]; Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia [PNURSP2022R95]; Deanship of Scientific Research at King Khalid University, Saudi Arabia [R. G.P.1:255/43]

作者

  • S

    Sardar, Asma (第一作者)

  • A

    Abid, Obaid-ur-Rahman (通讯)

查看全部 12 位作者收起作者
  • D

    Daud, Saima

  • S

    Shah, Basit Ali

  • S

    Shahid, Wardah

  • A

    Ashraf, Muhammad

  • F

    Fatima, Mahvish

  • E

    Ezzine, Safa

  • W

    Wadood, Abdul

  • S

    Shareef, Azam

  • A

    Al-Ghulikah, Hanan A.

  • A

    Alissa, Siham A.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417